​

Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JAZZ Stock Forecast

Jazz Pharmaceuticals (JAZZ) stock forecast, based on 48 Wall Street analysts, predicts a 12-month average price target of $287.93, with a high of $322.00 and a low of $229.00. This represents a 19.32% increase from the last price of $241.31.

$100 $150 $200 $250 $300 $350 High: $322 Avg: $287.93 Low: $229 Last Closed Price: $241.31

JAZZ Stock Rating

Jazz Pharmaceuticals stock's rating consensus is Buy, based on 48 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 43 Buy (89.58%), 5 Hold (10.42%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 48 0 5 43 Strong Sell Sell Hold Buy Strong Buy

JAZZ Price Target Upside V Benchmarks

TypeNameUpside
StockJazz Pharmaceuticals19.32%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%
IdeaCannabis Stocks List189.52%

Price Target Trends

1M3M12M
# Anlaysts92546
Avg Price Target$293.67$287.00$260.13
Last Closing Price$241.31$241.31$241.31
Upside/Downside21.70%18.93%7.80%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 267111-120
Aug, 267111-120
Jul, 267101-119
Jun, 267101-119
May, 26692--17
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 10, 2026Barclays$271.00$241.3112.30%12.30%
Aug 28, 2026Leonid TimashevRBC Capital$299.00$247.4520.83%23.91%
Aug 26, 2026Leonid TimashevRBC Capital$277.00$257.547.56%14.79%
Aug 26, 2026Gregory RenzaTruist Financial$281.00$257.049.32%16.45%
Aug 26, 2026Morgan Stanley$322.00$257.5225.04%33.44%
Aug 26, 2026Needham$310.00$260.2319.13%28.47%
Aug 26, 2026Gary NewmanCanaccord Genuity$300.00$260.2315.28%24.32%
Aug 26, 2026David HoangDeutsche Bank$300.00$260.2315.28%24.32%
Aug 11, 2026Morgan Stanley$283.00$252.2012.21%17.28%
Aug 04, 2026Deutsche Bank$287.00$252.5613.64%18.93%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 26, 2026RBC CapitalOutperformOutperformhold
Aug 26, 2026Morgan StanleyOverweightOverweighthold
Aug 26, 2026NeedhamBuyBuyhold
Aug 26, 2026Deutsche BankBuyBuyhold
Aug 04, 2026Deutsche BankBuyBuyhold
Aug 04, 2026Morgan StanleyOverweightOverweighthold
Aug 04, 2026Cowen & Co.BuyBuyhold
Aug 04, 2026NeedhamBuyBuyhold
Aug 04, 2026UBSBuyBuyhold
Aug 04, 2026Wells FargoOverweightOverweighthold

Financial Forecast

EPS Forecast

$-10 $-1 $8 $17 $26 $35 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-5.51$-3.58$6.55$9.06$-5.84---
Avg Forecast$15.67$13.56$18.50$20.21$21.88$22.40$25.00$26.78
High Forecast$16.42$14.21$18.73$20.49$23.81$26.66$31.99$28.52
Low Forecast$14.81$12.76$18.16$19.74$19.59$16.18$14.90$25.04
Surprise %-135.16%-126.40%-64.59%-55.17%-126.69%---

Revenue Forecast

$3B $3B $4B $4B $5B $6B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.09B$3.66B$3.83B$4.07B$4.27B---
Avg Forecast$3.06B$3.66B$3.83B$4.04B$4.31B$4.48B$4.76B$5.04B
High Forecast$3.18B$3.79B$3.93B$4.06B$4.53B$4.49B$4.78B$5.30B
Low Forecast$2.93B$3.49B$3.78B$4.01B$4.10B$4.46B$4.73B$4.79B
Surprise %1.04%0.00%0.02%0.76%-0.98%---

Net Income Forecast

$-500M $100M $700M $1B $2B $3B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-328.95M$-224.06M$414.83M$560.12M$-356.15M---
Avg Forecast$1.13B$177.38M$414.83M$1.45B$1.56B$1.54B$1.69B$1.93B
High Forecast$1.18B$226.81M$530.42M$1.48B$1.72B$1.92B$2.31B$2.06B
Low Forecast$1.07B$127.96M$299.25M$1.42B$1.41B$1.17B$1.07B$1.80B
Surprise %-129.13%-226.31%--61.36%-122.77%---

JAZZ Forecast FAQ

Is Jazz Pharmaceuticals stock a buy?

Jazz Pharmaceuticals stock has a consensus rating of Buy, based on 48 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 43 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jazz Pharmaceuticals is a favorable investment for most analysts.

What is Jazz Pharmaceuticals's price target?

Jazz Pharmaceuticals's price target, set by 48 Wall Street analysts, averages $287.93 over the next 12 months. The price target range spans from $229 at the low end to $322 at the high end, suggesting a potential 19.32% change from the previous closing price of $241.31.

How does Jazz Pharmaceuticals stock forecast compare to its benchmarks?

Jazz Pharmaceuticals's stock forecast shows a 19.32% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%), trailing the Cannabis Stocks List (189.52%) investment idea.

What is the breakdown of analyst ratings for Jazz Pharmaceuticals over the past three months?

  • September 2026: 35.00% Strong Buy, 55.00% Buy, 5.00% Hold, 0% Sell, 5.00% Strong Sell.
  • August 2026: 35.00% Strong Buy, 55.00% Buy, 5.00% Hold, 0% Sell, 5.00% Strong Sell.
  • July 2026: 36.84% Strong Buy, 52.63% Buy, 5.26% Hold, 0% Sell, 5.26% Strong Sell.

What is Jazz Pharmaceuticals’s EPS forecast?

Jazz Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $22.4, marking a -483.56% decrease from the reported $-5.84 in 2025. Estimates for the following years are $25 in 2027, and $26.78 in 2028.

What is Jazz Pharmaceuticals’s revenue forecast?

Jazz Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $4.48B, reflecting a 4.94% increase from the reported $4.27B in 2025. The forecast for 2027 is $4.76B, and $5.04B for 2028.

What is Jazz Pharmaceuticals’s net income forecast?

Jazz Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $1.54B, representing a -533.44% decrease from the reported $-356M in 2025. Projections indicate $1.69B in 2027, and $1.93B in 2028.